Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

NEW HAVEN, Conn., Aug. 15 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that it had accrued a total of 85 patients to the pivotal Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in previously untreated elderly patients with de novo poor-risk acute myelogenous leukemia (AML).

Alan Kessman, Chief Executive Officer said, "We are extremely pleased to have reached this milestone in the pivotal Phase II trial of our lead anticancer agent. We will now proceed to analyze the data and, if warranted, prepare a New Drug Application for submission to the U.S. Food and Drug Administration in 2008." He added, "We continue to plan on the release of preliminary data from this trial at the American Society of Hematology (ASH) Meeting in December."

The pivotal Phase II trial, initiated in May 2006, is evaluating Cloretazine(R) (VNP40101M) as a single agent in previously untreated AML patients over the age of 60 with de novo poor-risk AML. Patients are eligible for this trial if they are at least 60 years of age with de novo AML and have one of the following additional risk factors: (i) unfavorable cytogenetics; (ii) an ECOG performance status of 2 or greater; or (iii) a co-morbid condition that precludes them from receiving cytotoxic therapy with cytarabine and an anthracycline. Patients over the age of 70 with de novo AML who do not have favorable cytogenetics are also eligible.

The primary endpoint for this trial is the complete response rate (including complete remission (CR) and complete remission with incomplete platelet recovery (CRp)). Secondary endpoints include overall survival, disease-free survival and progression-free survival.

The trial ha
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... MONMOUTH JUNCTION, N.J. , Nov. 21, 2014 ... immunotherapy company commercializing its European Union approved CytoSorb® ... countries worldwide, was awarded the Beacon of Light ... Annual Awards Celebration.  Dr. ... stated, "It is an honor to be recognized ...
(Date:11/22/2014)... 21 de noviembre de 2014  BioClinica®, Inc., ... externalizados y tecnologías eClinical, ha indicado un aumento ... inteligente, para el seguimiento basado en el riesgo ... el concepto del seguimiento basado en el riesgo ... visitas de seguimiento o cambio de los métodos ...
(Date:11/22/2014)... Calif. , Nov. 21, 2014   Long Beach ... implants are often called the gold standard in tooth replacement ... are a stable, long-lasting way to restore and preserve smiles ... implants to replace a missing tooth or as a part ... transform the look and feel of a smile. ...
Breaking Medicine Technology:CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3Long Beach Dentist, Dr. Rassouli, is Now Offering Dental Implants 2
... Pharmaceuticals, Inc. (NASDAQ: SVNT ) today reported financial ... ended the quarter with $268.0 million in cash and short-term ... primarily due to the issuance and sale of $230 million ... of 2011, the Company had a net loss of $13.5 ...
... 5, 2011 Delcath Systems, Inc. (NASDAQ: DCTH ... Annual JMP Securities Research Conference on Wednesday, May ... David McDonald, Chief Financial Officer, will provide an overview of ... Attendance at this conference is by invitation only. Delcath ...
Cached Medicine Technology:Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 2Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 3Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 4Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 5Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 6Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 7Delcath to Present at the JMP Securities Research Conference 2Delcath to Present at the JMP Securities Research Conference 3
(Date:11/22/2014)... Washington, DC (PRWEB) November 22, 2014 ... its monthly Tech Report , which features the ... Sofastaii, a technology expert and reporter for NewsWatch, conducted ... can easily improve the flavor of your water. , ... are everywhere. It’s important that everything is done to ...
(Date:11/22/2014)... November 22, 2014 A Xarelto lawsuit has ... who is seeking $10 million in damages from the makers ... According to the lawsuit, the woman began using Xarelto in ... alleges in her lawsuit she suffered life-threatening bleeding in July ... injuries, pain, suffering and emotional distress. The lawsuit purports that ...
(Date:11/22/2014)... 2014 (HealthDay News) -- Many young people consider hookahs ... new study finds fumes from the water pipes contain ... an increased risk for leukemia in prior research, according ... journal Cancer Epidemiology, Biomarkers & Prevention . ... is not a safe alternative to smoking other forms ...
(Date:11/22/2014)... Steven Reinberg HealthDay Reporter ... are better when patients are treated in an ambulance by ... German researchers report. The sooner patients get the clot ... outcome after a stroke, the researchers noted. For the best ... hour after stroke symptoms start, the researchers said. "The ...
(Date:11/22/2014)... Amy Norton HealthDay Reporter ... adults who live in nursing homes may commonly deal with ... suggests. The study of 10 centers in New York ... nearly 20 percent of residents were involved in some type ... was a verbal clash, with someone yelling or cursing at ...
Breaking Medicine News(10 mins):Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 2Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 3Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 4Health News:Hookahs Deliver Toxic Benzene in Every Puff, Study Shows 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 3Health News:Senior-to-Senior Aggression Common in U.S. Nursing Homes 2Health News:Senior-to-Senior Aggression Common in U.S. Nursing Homes 3
... revenues, which results in 6 percent lower full-year revenue ... 2 percent increase in diluted earnings per share compared ... (NYSE: HI ) is revising its 2009 ... its second fiscal quarter. For the full 2009 fiscal ...
... dermatological drug developmentPETALUMA, Calif., April 9 Dow ... hold a 1-day workshop on "Topical Dermatological Product ... the Hilton East Brunswick, New Jersey. This workshop ... confronted during development of topical dermatological drugs intended ...
... LCA-Vision Inc. (Nasdaq: LCAV ), a leading provider ... brand, today announced that it will release first quarter 2009 ... 2009. A conference call and webcast to discuss the ... at 10:00 a.m. Eastern time.To access the conference call, dial ...
... Fiber SupplementYUBA CITY, Calif., April 9 For people ... relief, there is now a clinically proven, natural solution ... are discovering that Sunsweet PlumSmart helps maintain a regular ... Internet Journal of Nutrition and Wellness ( ...
... leader in adult stem cell research and manufacturing, announced today the ... S.A. headquartered in the Biopôle Technology and Business Park located in ... ... (PRWEB) April 9, 2009 -- Stemedica Cell Technologies , Inc. ...
... 9 Boston Celtics Captain Paul Pierce teamed up ... Restaurants: Paul Pierce,s Favorites for Healthy Dining", which highlights ... Popular restaurants in Boston. Utilizing the trusted ratings and ... the opinions of 6,767 avid local diners, Paul Pierce,s ...
Cached Medicine News:Health News:Hillenbrand Expects to Report Second-Quarter Net Revenue of $170.8 Million and Revises 2009 Guidance 2Health News:Hillenbrand Expects to Report Second-Quarter Net Revenue of $170.8 Million and Revises 2009 Guidance 3Health News:Hillenbrand Expects to Report Second-Quarter Net Revenue of $170.8 Million and Revises 2009 Guidance 4Health News:Hillenbrand Expects to Report Second-Quarter Net Revenue of $170.8 Million and Revises 2009 Guidance 5Health News:Hillenbrand Expects to Report Second-Quarter Net Revenue of $170.8 Million and Revises 2009 Guidance 6Health News:LCA-Vision to Announce First Quarter 2009 Financial Results on Tuesday, April 28, 2009 2Health News:PlumSmart Plum Juice Clinically Proven to Help Regulate Digestion, Naturally 2Health News:PlumSmart Plum Juice Clinically Proven to Help Regulate Digestion, Naturally 3Health News:Stemedica Expands Globally With International Headquarters In Switzerland 2Health News:Stemedica Expands Globally With International Headquarters In Switzerland 3Health News:Stemedica Expands Globally With International Headquarters In Switzerland 4Health News:Stemedica Expands Globally With International Headquarters In Switzerland 5Health News:Captain of the Boston Celtics and 2008 NBA Finals MVP Paul Pierce Partners With Zagat Survey to Spotlight Healthy Dining in Boston 2Health News:Captain of the Boston Celtics and 2008 NBA Finals MVP Paul Pierce Partners With Zagat Survey to Spotlight Healthy Dining in Boston 3
Each handle is designed to fit a specific trephine size....
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Medicine Products: